異動解讀｜康方生物盤中上漲5.3%，依沃西HARMONi-2研究OS期中分析達關鍵次要終點

行情直擊

09/03

9月3日，康方生物盤中上漲5.3%，報92.45港元，成交額8752.33萬港元。

消息面上，康方生物當日發布公告，其自主研發的全球首創PD-1/VEGF雙特異性抗體依沃西單藥對比帕博利珠單藥，用於一線治療PD-L1表達陽性局部晚期或轉移性非小細胞肺癌的III期臨床研究HARMONi-2，經獨立數據監察委員會評估的預先設定總生存期（OS）期中分析達到關鍵次要終點，取得具有統計學顯著和臨床獲益的陽性結果。該研究共入組398例受試者。此前依沃西已在膽道癌III期HARMONi-GI1中頭對頭擊敗度伐利尤取得OS陽性結果，第三個適應症一線治療鱗狀NSCLC亦於8月獲批上市。國金證券、國信證券等多家機構維持買入或優於大市評級，看好核心產品放量加速。

（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/news/1167408843"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167408843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167408843?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-03 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167408843","market":"hk","top_or_hot":-1,"title":"異動解讀｜康方生物盤中上漲5.3%，依沃西HARMONi-2研究OS期中分析達關鍵次要終點","media":"行情直擊","content":"<p><p>9月3日，康方生物盤中上漲5.3%，報92.45港元，成交額8752.33萬港元。</p><p>消息面上，康方生物當日發布公告，其自主研發的全球首創PD-1/VEGF雙特異性抗體依沃西單藥對比帕博利珠單藥，用於一線治療PD-L1表達陽性局部晚期或轉移性非小細胞肺癌的III期臨床研究HARMONi-2，經獨立數據監察委員會評估的預先設定總生存期（OS）期中分析達到關鍵次要終點，取得具有統計學顯著和臨床獲益的陽性結果。該研究共入組398例受試者。此前依沃西已在膽道癌III期HARMONi-GI1中頭對頭擊敗度伐利尤取得OS陽性結果，第三個適應症一線治療鱗狀NSCLC亦於8月獲批上市。國金證券、國信證券等多家機構維持買入或優於大市評級，看好核心產品放量加速。</p><p>（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>異動解讀｜康方生物盤中上漲5.3%，依沃西HARMONi-2研究OS期中分析達關鍵次要終點</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n異動解讀｜康方生物盤中上漲5.3%，依沃西HARMONi-2研究OS期中分析達關鍵次要終點\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1059448697\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">行情直擊 </p>\n<p class=\"h-time smaller\">2026-09-03 09:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>9月3日，康方生物盤中上漲5.3%，報92.45港元，成交額8752.33萬港元。</p><p>消息面上，康方生物當日發布公告，其自主研發的全球首創PD-1/VEGF雙特異性抗體依沃西單藥對比帕博利珠單藥，用於一線治療PD-L1表達陽性局部晚期或轉移性非小細胞肺癌的III期臨床研究HARMONi-2，經獨立數據監察委員會評估的預先設定總生存期（OS）期中分析達到關鍵次要終點，取得具有統計學顯著和臨床獲益的陽性結果。該研究共入組398例受試者。此前依沃西已在膽道癌III期HARMONi-GI1中頭對頭擊敗度伐利尤取得OS陽性結果，第三個適應症一線治療鱗狀NSCLC亦於8月獲批上市。國金證券、國信證券等多家機構維持買入或優於大市評級，看好核心產品放量加速。</p><p>（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1167408843","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167408843","pubTimestamp":1788399072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直擊","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"9月3日，康方生物盤中上漲5.3%，報92.45港元，成交額8752.33萬港元。該研究共入組398例受試者。此前依沃西已在膽道癌III期HARMONi-GI1中頭對頭擊敗度伐利尤取得OS陽性結果，第三個適應症一線治療鱗狀NSCLC亦於8月獲批上市。國金證券、國信證券等多家機構維持買入或優於大市評級，看好核心產品放量加速。（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物"},"translate_title":"Unusual Movement Analysis | Akeso Biologics rose 5.3% intraday after the interim analysis of the OS study of Evosi HARMONi-2 reached a key secondary endpoint.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"9月3日，康方生物盤中上漲5.3%，報92.45港元，成交額8752.33萬港元。消息面上，康方生物當日發布公告，其自主研發的全球首創PD-1/VEGF雙特異性抗體依沃西單藥對比帕博利珠單藥，用於一線治療PD-L1表達陽性局部晚期或轉移性非小細胞肺癌的III期臨床研究HARMONi-2，經獨立數據監察委員會評估的預先設定總生存期（OS）期中分析達到關鍵次要終點，取得具有統計學顯著和臨床獲益的陽性結果。該研究共入組398例受試者。此前依沃西已在膽道癌III期HARMONi-GI1中頭對頭擊敗度伐利尤取得OS陽性結果，第三個適應症一線治療鱗狀NSCLC亦於8月獲批上市。國金證券、國信證券等多家機構維持買入或優於大市評級，看好核心產品放量加速。（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}